Prognostic determinants in lupus nephritis: a long-term clinicopathologic study

Abstract

Over the past 50 years, survival has improved in patients with systemic lupus erythematosus and associated nephritis. Yet, there are few long-term outcome studies in patients with well-defined nephropathy. We examinbed the outcome of 439 patients with lupus nephritis who were seen at the Mayo Clinic between 1964 and 1986 in whom renal biopsies were assessed using the World Health Organization (WHO) classification. There were 341 women and 98 men (mean ± s.d., age 33.5 ± 14 years); 200 (46%) patients were hypertensive and 249 (57%) had impaired renal function at renal biopsy. All WHO morphologic classes were represented and 339 (77%) patients had class III, IV and V (the more severe forms of nephritis). Follow-up averaged 10.2 years per patient. At last contact, 286 (65%) patients were alive and 153 (35%) were dead. Overall patient survival was 80%, 69% and 53% at 5, 10 and 20 years after biopsy that was significantly worse than expected survival (P < 0.001). Ten-year cumulative patient survival improved comparing earlier to more recent time spans: 64% in 231 patients seen during 1964-75; 76% in 2089 patients studied during 1976-86 (P = 0.03). Survival free of renal failure was 83%, 74% and 64% at 5, 10 and 20 years, and survival was unfavorably influenced by progressive WHO class, hypertension, impaired renal function, nephrotic range proteinuria, hypoalbuminemia and anemia. Multivariate analysis found impaired renal function, increased urine protein, anemia and younger age to be independent predictors of renal failure. WHO class was not a significant predictor when adjusted for these four factors. Cardiovascular events accounted for 48% of the known deaths and were equally distributed across all WHO classes, followed by infections, renal failure, malignancy, respiratory failure and gastrointestinal bleeding. Severe nephritis, nephrotic syndrome, hypertension and anemia remain strong predictors of a poor renal outcome. Prospective randomized studies stratifying for these factors are needed to find optimal immunosuppressive regimens to improve renal survival.

Keywords

lupus nephritis prognosis pathology

Get full access to this article

View all access options for this article.

References

Ginzler EM et al. A multicenter study of outcome in systemic lupus erythematosus. I. Study variables as predictors of prognosis. Arthritis Rheum 1982; 25: 601-611.

Rosner S. et al. A multicenter study of outcomes in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982; 25: 612-617.

Jonsson H. , Nived O. , Sturfelt G. Outcome in systemic lupus erythematosus. A prospective study of patients from a defined population. Medicine 1989; 68: 141-150.

Wallace DJ Prognostic subsets and mortality in systemic lupus erythematosus. In: Wallace DJ , Hahn BH (eds). Dubois' Lupus Erythematosus, 4th edn. Philadelphia: Lea & Febiger, 1993: 606-615.

Esdaile JM et al. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis. A study of 87 patients and review of the literature. Q J Med 1989; 72: 779-833.

Nossent HC et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis. Analysis of 116 patients. Arthritis Rheum 1990, 33: 970-977.

Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Lupus nephritis. Prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 1992; 19: 473-479.

Donadio JV Jr , Holley KE , Ilstrup DM Cytotoxic drug treatment of lupus nephritis . Am J Kidney Dis 1982; 2: 178-181.

Felson DT , Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984; 311: 1528-1533.

10.

Austin HA III et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.

11.

Balow JE et al. Lupus nephritis. NIH Conference. Ann Intern Med 1987; 106: 79-94.

12.

Donadio JV Jr , Glassock RJ Immunosuppressive drug therapy in lupus nephritis . Am J Kidney Dis 1993; 21: 239-250.

13.

Cameron JS What is the role of long-term cytotoxic agents in the treatment of lupus nephritis ? J Nephrol 1993; 6: 172-176.

14.

Austin HA III et al. Predicting renal outcomes in severe lupus nephritis. Contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550.

15.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.

16.

Kaplan EL , Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.

17.

Cox DR Regression models and life tables (with discussion). J R Stat Soc 1972; B34: 187-220.

18.

Wallace DJ et al. Lupus nephritis. Experience with 230 patients in a private practice from 1950 to 1980. Am J Med 1982; 72: 209-220.

19.

McCurdy DK et al. Lupus nephritis. Prognostic factors in children. Pediatrics 1992; 89: 240-246.

20.

Austin HA III et al. Prognostic factors in lupus nephritis. Am J Med 1983; 75: 382-391.

21.

Appel GB et al. Long-term follow- up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-885.

22.

Esdaile JM et al. Predictors of one year outcome in lupus nephritis. The importance of renal biopsy. Q J Med 1991; 81: 907-918.

23.

Levey AS and the Lupus NBephritis Collaborative Study Group. Progression and remission of renal disease in the Lupus Nephrology Collaborative Study. Results of treatment with prednisone and short-term cyclophosphamide. Ann Intern Med 1992; 116: 114-123.

24.

Magil AB et al. Prognostic factors in diffuse proliferative lupus glomerulonephritis . Kidney Int 1988; 34: 511-517.

25.

Schwartz MM et al. The Lupus Nephritis Collaborative Study Group.Role of pathology indices in the management of severe lupus glomerulonephritis. Kidney Int 1992; 42: 738-748.

26.

Studenski S. et al. Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors. Arthritis Rheum 1987; 30: 1326-1332.

27.

Miller MH et al. Systemic lupus erythematosus in males. Medicine 1983; 62: 327-334.

28.

Whiting-O'Keefe Q. et al. The information content from renal biopsy in systemic lupus erythematosus. Step-wise linear regression analysis . Ann Intern Med 1982; 96: 718-723.

29.

Urowitz MB et al. The bimodal mortality pattern of systemic lupus erythematosus . Am J Med 1976; 60: 221-225.

30.

Rubin LA , Urowitz MB , Gladman DD Mortality in systemic lupus erythematosus. The bimodal pattern revisited. Q J Med 1985; 55: 87-98.

31.

Haider YS , Roberts WC Coronary arterial disease in systemic lupus erythematosus. Am J Med 1981; 70: 775-781.

32.

Kawai S. , Fukuda Y. , Okada R. Atherosclerosis of the coronary arteries in collagen disease and allied disorders . Jpn Circ J 1982; 46: 1208-1221.

33.

Mandell BF Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum 1987; 17: 126-141.

34.

Love PE , Santoro SA Antiphospholipid antibodies. Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-698.

35.

Ballou SP , Khan MA , Kushner I. Clinical features of systemic lupus erythematosus. Differences related to race and age of onset. Arthritis Rheum 1982 ; 25: 55-60.